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Background: There is considerable unexplained heterogeneity in previous meta-analyses of randomized controlled
trials (RCTs) evaluating the effects of patient decision aids on the accuracy of knowledge of outcome probabilities.
The purpose of this review was to explore possible effect modification by three covariates: the type of control
intervention, decision aid quality and patients' baseline knowledge of probabilities.
Methods: A sub-analysis of studies previously identified in the 2011 Cochrane review on decision aids for people
facing treatment and screening decisions was conducted. Additional unpublished data were requested from
relevant study authors to maximize the number of eligible studies. RCTs (to 2009) comparing decision aids with
standardized probability information to control interventions (lacking such information) and assessing the accuracy
of patient knowledge of outcome probabilities were included. The proportions of patients with accurate knowledge
of outcome probabilities in each group were converted into relative effect measures. Intervention quality was
assessed using the International Patient Decision Aid Standards instrument (IPDASi) probabilities domain.
Results: A main effects analysis of 17 eligible studies confirmed that decision aids significantly improve the
accuracy of patient knowledge of outcome probabilities (relative risk = 1.80 [1.51, 2.16]), with considerable
heterogeneity (87%). The type of control did not modify effects. Meta-regression suggested that the IPDASi
probabilities domain score (reflecting decision aid quality) is a potential effect modifier (P = 0.037), accounting for a
quarter of the variability (R2 = 0.28). Meta-regression indicated the control event rate (reflecting baseline knowledge)
is a significant effect modifier (P = 0.001), with over half the variability in ln(OR) explained by the linear relationship
with log-odds for the control group (R2 = 0.52); this relationship was slightly strengthened after correcting for the
statistical dependence of the effect measure on the control event rate.
Conclusions: Patients’ baseline level of knowledge of outcome probabilities is an important variable that explains
the heterogeneity of effects of decision aids on improving accuracy of this knowledge. Greater relative effects are
observed when the baseline proportion of patients with accurate knowledge is lower. This may indicate that
decision aids are more effective in populations with lower knowledge.
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In systematic reviews of binary outcomes, heterogeneity
conventionally refers to the variation in relative effects
(relative risk, odds ratio) across studies that is greater than
one would expect by chance [1]. The causes of such
study-level variation can either be artifactual, where meth-
odological differences between studies affect the relative
effect measures, or real, where differences may be attribut-
able to variation across studies in factors related to the
population included, active interventions used or compar-
ators employed [2,3]. When present, unexplained hetero-
geneity complicates the interpretation and usefulness of
pooled effect estimates of meta-analyses in decision-
making. It is for this reason that the quality of pooled evi-
dence is typically downgraded when assessed using the
GRADE framework [4]. Attempts to explain sources of
heterogeneity are important for overcoming these limi-
tations and for their potential to contribute knowledge
about what types of patients benefit most from a specific
intervention [2,3,5,6]. The Cochrane meta-analysis of ran-
domized controlled trials (RCTs) evaluating patient deci-
sion aid effects on the accuracy of knowledge of outcome
probabilities is an example where interpretation of the
pooled effect has been hampered by high heterogeneity.
Patient decision aids are complex interventions used to
help patients make specific and deliberative choices
among treatment or screening options by providing, at the
minimum, information on the options and associated out-
comes relevant to the patient’s health status, and implicit
methods to clarify their values or preferences [7]. Due to
their complex nature – involving multiple interacting
components and behaviors – and the diverse clinical set-
tings they are designed for, the exact form of the interven-
tion and populations in which they are evaluated vary
considerably. There is thus a corresponding expectation of
variation in real decision aid effects across conditions.
The effects of decision aids on numerous decision-
related outcomes have been extensively evaluated. Since
patients are known to underestimate probabilities of
harms or overestimate probabilities of benefits [8], deci-
sion aids are often designed to communicate estimates
of probabilities derived from population-based research.
Such probabilities apply to possible outcomes of the fea-
tured decisions: benefits and harms of an intervention,
or true- and false-positive or -negative screening results
[9]. Studies that evaluate the effects of decision aids on
the accuracy of patient knowledge of these outcome
probabilities generally measure the proportion of pa-
tients who are able to correctly answer questions about
population-derived probability estimations – making this
a binary outcome.
The most recent (2011) update to the Cochrane sys-
tematic review on patient decision aids includes 86 RCTs
where the authors reviewed 23 different outcomes [7].Accuracy of knowledge of outcome probabilities (labeled
‘accurate risk perception’ in that review) was the second-
most frequently measured outcome, and the results of 14
studies were pooled. Meta-analysis revealed a uniform dir-
ection of effect favoring decision aids across all studies, and
the pooled effect estimate was significant (relative risk =
1.74 [1.46 to 2.08], P < 0.001). The level of heterogeneity,
however, was significant (P < 0.001) and considerable (I2 =
83%). Despite this, the pooled effect is considered inform-
ative to a degree since decision aids showed a uniformly
positive effect. However, the Cochrane review mentions
that ‘the pooled effect size and CI should be interpreted as
a range across conditions, which may not be applicable to
a specific condition’ [10], reflecting the limitation to the in-
terpretability and utility of the pooled random effects esti-
mates found in meta-analyses when there exists substantial
real variation in intervention effects. In other words, the
pooled estimate does not correspond to any individual de-
cision aid, setting or population. Furthermore, it is impos-
sible to predict where any given decision aid would lie
within the wide range of possible relative effects [3].
The 2011 Cochrane update [7] tentatively explored two
sources of heterogeneity affecting this outcome. First, it
showed that the effect size of decision aids in which prob-
abilities were represented numerically is larger than for
those where probabilities were described with words,
suggesting possible effect modification attributable to this
specific aspect of the intervention. Secondly, removing
three (of 14) studies with the lowest control event rate (se-
lected as outliers by visual inspection) reduced heterogen-
eity to non-significant levels (P = 0.3), implicating control
levels of accurate knowledge as a potential contributor to
heterogeneity [10]. While informative, these preliminary
analyses were not selected with any overall rationale and
did not provide formal tests for effect modification.
The current investigation aims to improve interpretabil-
ity and usefulness of the available research evidence re-
garding decisions aid effects on the accuracy of patient
knowledge of outcome probabilities by exploring and
characterizing potential contributors to the observed het-
erogeneity [2-4]. Subgroup analysis and meta-regression
were employed to investigate the potential effects of three
study-level factors (covariates): the type of control inter-
vention, the level of decision aid quality and the control
event rate. These covariates were chosen because they
represent the best available measures that summarize or
combine relevant characteristics of the comparator (con-
trol), active intervention or study population, respectively.
Methods
As a sub-analysis of the previous Cochrane systematic
review on decision aids [7], certain aspects of the original
methods were not repeated in detail here – principally
the literature search and parts of the literature
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sulted for further information on individual studies,
including setting, patients included, intervention charac-
teristics and risk of bias assessments.
Data sources and study selection
Studies previously identified through electronic database
searches (MEDLINE, PsycINFO, CINAHL, EMBASE,
Cochrane Central Controlled Trials Register) in the 2011
Cochrane review served as the basis for study selection
[7]. Thus, RCTs published up to December 2009 meeting
the original selection criteria were considered. As an add-
itional criterion, we included studies where data had been
collected on the proportions of participants in both inter-
vention and control groups who had accurate knowledge
of outcome probabilities post-intervention. To maximize
the number of studies available for analysis, the 86 pub-
lications included in the 2011 Cochrane update were
rescreened to identify studies where the relevant outcome
data might exist but had not been previously published.
The corresponding authors were then emailed up to three
times requesting unpublished data used to calculate rela-
tive risks and copies of the original decision aids.
Data extraction
Data from all studies were extracted in duplicate (SG,
MA) using piloted forms. In addition to newly eligible
studies, data were re-extracted from the set of 14 studies
pooled in the 2011 Cochrane update [7]. In cases of dis-
agreement with the outcome data from the previous
Cochrane review, its authors (CB, DS) were consulted
and consensus was reached on which data to use for the
current review.
Event rates, defined as the proportion of patients in the
decision aid group correctly answering questions about
probabilities divided by that in the control group, were
extracted for calculating relative risk. In eight studies that
evaluated knowledge of outcome probabilities with more
than one question, the proportion of correct answers was
averaged. For purposes of GRADE assessment, the risk of
bias items applicable at the outcome level (blinding, in-
complete outcome data, specifically for assessments of
knowledge of probabilities) were abstracted, as these items
were previously reported in the Cochrane update [7] only
at the study level. Information for the three covariates ana-
lyzed was abstracted (described below).
Selection of study-level factors (covariates) investigated
Study-level factors with the potential to contribute to
heterogeneity (covariates) were considered to represent
three principal sources of clinical heterogeneity: charac-
teristics of the comparator (control), the active interven-
tion and the population [2]. To minimize the risk of
detecting spurious effect modification due to multiplecomparisons, only one covariate was selected to represent
each main source, to give a total of three [11,12]. In each
case, the covariates were selected for their availability and
biologic plausibility (likelihood based on a mechanistic ra-
tionale) as substantial contributors to heterogeneity [11].
For the first category, comparator (or control), only one
covariate was available and therefore selected: the type of
control intervention. Since multiple covariates were avail-
able corresponding to characteristics of active intervention
and study population, a top-down approach was used in
which the best available measure that combined poten-
tially relevant characteristics was selected in each case. To
represent intervention characteristics, a composite meas-
ure of relevant decision aid quality characteristics was
chosen. For population characteristics, the control event
rate was chosen because it provides a convenient sum-
mary measure [13]. The rationale, hypothesis and meas-
urement for each covariate are described below.
Type of control intervention
Depending on the context, not all studies evaluating de-
cision aids provide the same degree of standardized in-
formation to the control group [7]. Three types of
control intervention, from less to more standardized in-
formation, are categorized: (1) no standardized infor-
mation other than usual care; (2) generic standardized
information used as a sham, such as basic background
on the disease, and containing no outcome information
or (3) information on outcomes associated with options,
sometimes considered as a less intense form of decision
aid. In all cases, control interventions differ from the ex-
perimental intervention by providing no information on
outcome probabilities. Higher levels of standardized in-
formation may have a hidden effect on patients’ ability
to answer questions about probabilities. The hypothesis
for this covariate was that control interventions that
provide more standardized information to the control
group, because they may conceivably improve control
patients’ ability to answer questions about probabilities,
would decrease relative effect size. Possible effect modi-
fication by this categorical covariate was investigated
with subgroup analysis.
Decision aid quality
The International Patient Decision Aid Standards
(IPDAS) collaboration has developed an instrument, the
IPDASi, for rating the quality of decision aids [14].
IPDASi includes a probabilities dimension consisting of
eight items corresponding to theoretical elements de-
rived from systematic review of the evidence on effective
formats for communicating outcome probabilities to
patients [15]. The items address factors including the
presentation of event rates, specification of a time
period, the allowing for comparison of probabilities
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around probabilities, the provision of multiple ways of
viewing probabilities (for example, words, numbers and
diagrams) and providing balanced information to limit
framing biases [14]. The probabilities dimension therefore
represents a comprehensive composite measure of rele-
vant decision aid characteristics likely to affect knowledge
of probabilities. Moreover, its continuous scale probably
gives greater statistical power when testing for effect
modification than does an equivalent categorical variable.
The hypothesis for this covariate was that decision aid
scores on the IPDASi probabilities dimension would in-
crease as the effectiveness of decision aids for improving
knowledge of outcome probabilities increases – which, if
true, would support the predictive validity of the probabil-
ities dimension of IPDASi [14]. Decision aids were scored
in duplicate by trained raters on a scale from 1 to 4 points
for each of 8 items in this dimension (scores provided by
NJW). The possible ratings of 8 to 32 were re-scaled to a
range of 0% to 100%. The effects of this continuous covari-
ate were investigated with meta-regression.
Control event rate
The control event rate (CER) in this context is the pro-
portion of patients in the control group who correctly
answer specific questions about probabilities. Note, ‘con-
trol event rate’ is used in preference to ‘baseline risk’ to
minimize confusion, since ‘risk’ in this case corresponds
to a favored outcome (that is, having accurate knowledge
of probabilities). Assuming the type of control interven-
tion does not modify its effects (and our investigations
found no evidence that it does), the control event rate
provides an estimate of the baseline level of accurate
knowledge of outcome probabilities in the population
studied. Patients’ baseline knowledge of these probabil-
ities may vary widely depending on factors such as
whether specific probabilities are likely to be common
knowledge, newness of the underlying evidence or pa-
tient education levels. The plausibility of effect modifica-
tion was first suggested in the 2009 Cochrane update
where heterogeneity was reduced to non-significant
levels after removing three studies with the lowest con-
trol event rate [10]. The hypothesis for this covariate
was that studies with higher control event rates have
lower relative risks. Effects due to this continuous covar-
iate were investigated with meta-regression.
Analysis
Three types of statistical analysis were performed: meta-
analysis of main effects, subgroup analysis to test for ef-
fect modification by the one categorical covariate (type
of control intervention) and meta-regression to test for
and characterize effect modification by the two continu-
ous covariates (decision aid quality and control eventrate). Each analysis type is described in further detail.
The threshold for statistical significance was P < 0.05.
Meta-analysis of main effects
Consistent with previous meta-analysis of the main ef-
fects for this outcome [7], relative risk was used as the
effect measure. The software Review Manager (RevMan,
version 5.1, Copenhagen, The Nordic Cochrane Centre,
The Cochrane Collaboration, 2011) was used to combine
estimates using the DerSimonian and Laird random-
effects model. Tau-squared in this model provides an es-
timate of the between-study variance. A chi-squared test
was used to examine the strength of evidence about
whether heterogeneity is present, and I2 provides an esti-
mate of its magnitude.
Subgroup analysis (type of control intervention)
Potential effect modification by the three types of control
intervention was tested with a weighted one-way ANOVA.
To provide additional support for a lack of effect on the
control event rate, a weighted ANOVA between type of
control intervention and control event rate was per-
formed. ANOVAs were calculated using the software IBM
SPSS Statistics (version 20.0 for Windows, Armonk, NY,
IBM Corp.), using the natural logarithm of the odds ratio,
ln(OR), as the effect measure for consistency with subse-
quent covariate analyses.
Meta-regression analysis (decision aid quality and control
event rate)
Univariate weighted least squares (WLS) meta-regression
analyses were conducted to test for and characterize po-
tential effect modification by IPDASi probabilities dimen-
sion score and control event rate, separately.
In selecting the most appropriate scales for these ana-
lyses, the effect measure was first considered. Changing
the effect measure (between relative risk (RR), OR, or ln
(OR)) and scale for representing the relationship has
been recommended as a strategy to minimize apparent
heterogeneity and effect modification as a first step in
reducing the chance of detecting a spurious interaction
in meta-regression where control event rate is a covari-
ate [6,16,17]. Of the three effect measures, ln(OR) had
the lowest heterogeneity (I2, Table 1) and was found in
exploratory analyses to have the least significant slope vs
control event rate, providing justification for using this
effect measure in the meta-regression. As additional jus-
tification, the natural log of the OR is commonly chosen
because it has better statistical properties since zero is
the value of no effect [6]. For the analysis of decision aid
quality, ln(OR) was plotted against the re-scaled IPDASi
probabilities dimension score (0% to 100%). For the ana-
lysis of control event rate, ln(OR) was plotted against
log-transformed values of the control event rate (that is,
Table 1 Study-level covariate values, observed effect size measures and pooled heterogeneity estimates listed in order












Lerman et al. [28] A 16 33 0.66 0.65 0.37 1.46 1.12
Johnson et al. [32] A 16 33 0.77 1.17 0.96 2.86 1.17
Wolf and Schorling
[24]
B 19 46 0.54 0.16 0.73 2.08 1.31
Whelan et al. [25] A 17 38 0.58 0.32 0.91 2.52 1.34
McBride et al. [27] A 23 63 0.30 −0.85 0.49 1.64 1.37
Schapira and
Vanruiswyk [23]
B 28 83 0.47 −0.10 0.89 2.45 1.45
Dodin et al. [31] B 26c 75 0.43 −0.28 0.82 2.32 1.48
O’Connor et al. [8] C 26c 75 0.46 −0.14 1.05 2.91 1.54
Whelan et al. [21] B 22 58 0.37 −0.53 0.82 2.29 1.55
Kuppermann et al.
[36]
C NA NA 0.32 −0.76 1.35 3.88 2.03
Vandemheen et al.
[37]
B 30 92 0.29 −0.88 1.52 4.67 2.26
McAlister et al. [29] A 29d 88 0.16 −1.62 1.11 3.06 2.29
Mathieu et al. [34] B 31 96 0.22 −1.29 1.54 4.71 2.62
Man-Son-Hing et al.,
[30]
A 29d 88 0.24 −1.16 1.83 6.32 2.80
Weymiller et al. [35] B 32 100 0.18 −1.48 1.88 6.94 3.38
Laupacis et al. [33] A 24 67 0.08 −2.34 1.50 4.88 3.72
Gattellari and Ward
[22]
B 21 54 0.10 −2.14 2.29 10.26 5.28
Chi-squared (heterogeneity) 55.75 56.41 120.19
I2 71% 72% 87%
a A, no standardized information; B, standardized generic information (no outcome information); C, simple decision aid (no standardized probability information).
b No continuity correction was applied to match Review Manager’s output.
c Same decision aid for both trials.
d Same decision aid for both trials.
CER, control event rate; IPDASi, International Patient Decision Aid Standards instrument; NA, full decision aid not available for rating; OR, odds ratio; RR, relative risk.
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scale making a linear model easier to interpret. With ln
(OR) as the common effect measure, exploratory multiple
regression combining the CER and IPDASi probabilities
dimension score could be performed more easily.
Since the selected effect measure ln(OR) is not avail-
able in RevMan, Excel was used to generate an equiva-
lent meta-analysis for ln(OR) to obtain the tau-based
weights for the meta-regressions. Excel formulae were
verified by comparing (non-continuity-corrected) back-
translated values to the RevMan output for OR. Event
frequencies for this meta-analysis were continuity-
corrected (adding 0.5). IBM SPSS Statistics was then
used to calculate standard WLS regressions using the
tau-based weights. Neither regression model (logit con-
trol vs ln(OR) or re-scaled IPDAS vs ln(OR)) was found
to violate the assumptions of linear regression (linearity,
independence, homoscedasticity and normality) upon
examination of the residual plots (predicted vs residual,independent vs residual and normal probability (Q-Q)
of residual plots).
The meta-regression against control event rate incor-
porated a bias correction. When baseline response rates
(control event rates) are used as the covariate in a meta-
regression, the measurement error in control event rate
and the functional dependence of the observed treat-
ment effect on the control group response can bias the
standard WLS regression and lead to incorrect inference
about the degree to which the control event rate modi-
fies effects and underlies heterogeneity [13,16,18]. This
problem was addressed using a modified WLS approach
developed previously [18], which considers sampling
error in the control event rate and generates bias terms
that are used to correct the standard regression coeffi-
cients. Bias terms and bias-corrected regression coeffi-
cients were calculated using Excel, the formulae for
which were verified using data from the original article
describing this approach [18].
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corrected regression formula for corresponding control
event rate values, back-translation was performed using
Excel.
GRADE assessment
The GRADE framework was employed to provide a
standardized summary rating of the pooled evidence for
the outcome of interest based on key quality dimensions:
risk of bias, consistency, directness, precision and publi-
cation bias [4,19,20]. The software GRADEpro (version
3.2 for Windows, 2008) was used.
Results
Meta-analysis of main effects
Of 86 studies from the 2011 Cochrane review, 17 studies
were included in the current meta-analysis of the effects
of decision aids on the accuracy of knowledge of out-
come probabilities [8,21-37]. Efforts to obtain additional
unpublished data resulted in three studies [32,34,35] be-
ing added to the 14 from the 2011 Cochrane analysis for
this outcome. The authors of three additional studies
who were contacted either confirmed that relevant data
was unavailable (n = 1) or were unable to provide data
(n = 2). Figure 1 shows the main pooled relative effect
for the outcome accuracy of patients’ knowledge of out-
come probabilities was significant, with a uniform direc-
tion of effect favoring decision aids (relative risk = 1.80
[1.51, 2.16]); heterogeneity was significant (P < 0.001)
and considerable (I2 = 87%).
Subgroup and meta-regression analysis of covariate
effects
Table 1 shows the covariate values and corresponding ef-
fect sizes for each study. For the subgroup analysis that
tested effect modification due to the type of controlFigure 1 Main effects of decision aids on patient knowledge of outco
relative risk.intervention used (no standardized information, generic
information or simple decision aid without probability in-
formation), the weighted ANOVA was not significant (F =
2.33, degrees of freedom, df = 2, P = 0.11). As further sup-
port for the lack of effect of the type of control interven-
tion on the control event rate, the second ANOVA
between these two covariates also lacked significance (F =
0.49, df = 2, P = 0.62).
Table 2 summarizes the relationships corresponding to
each of the two meta-regression analyses: decision aid
quality (rescaled IPDASi probabilities dimension score)
vs effect size, and log-transformed control event rate vs
effect size before and after bias correction.
The quality (IPDASi probabilities dimension scores) of
the decision aids evaluated in the included studies
ranged widely from 16 to 32 out of a total possible score
of 32 (33.3% to 100% when rescaled). The slope of the
univariate regression relationship between the rescaled
quality scores (%) and ln(OR) (Figure 2) was significant
(intercept 0.253, slope 0.013, P = 0.037), and accounted
for a quarter of the variability in effect size between
studies (R2 = 0.28).
The control event rate (representing the proportion of
control patients with accurate knowledge of outcome prob-
abilities) ranged widely among the 17 studies, from 0.08 to
0.77. The slope of the univariate regression between logit
control and ln(OR) in Figure 3, prior to bias correction
(dotted line), was significant (slope = −0.436; P = 0.001);
this relationship was slightly steeper (that is, strengthened)
after bias correction (solid line, slope = −0.466). In the non-
bias-corrected analysis, the control event rate accounted
for just over half of the variability in effect size (R2 = 0.52).
The multiple regression, which combined IPDASi
probabilities dimension score and control event rate,
was significant (P = 0.007) and accounted for slightly
more variability (R2 = 0.54). While effect modificationme probabilities. CI, confidence interval; df, degrees of freedom; RR,
Table 2 Regression coefficients for normalized IPDASi




(a) Normalized IPDASi probabilities
score vs ln(OR)
0.25 0.013 (0.006)
(b) logit control vs ln(OR), non-bias-
corrected
0.86 −0.436 (0.108)
logit control vs ln(OR), bias-
corrected
0.88 −0.466
IPDASi, International Patient Decision Aid Standards instrument; OR, odds ratio.
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model (P = 0.018), IPDASi probabilities dimension score
lost significance (P = 0.561).
GRADE assessment of evidence quality
The quality of the evidence supporting the use of deci-
sion aids for improving the accuracy of patient know-
ledge of outcome probabilities was assessed here as
‘moderate’ with the GRADE framework (Table 3). Dis-
regarding any explanation of sources of heterogeneity
provided in the current study, the same body of pooled
evidence would be assessed as ‘low’ (GRADE table not
shown) due to rating down for ‘inconsistency’.
Discussion
Our analysis of main effects of decision aids on the accur-
acy of patient knowledge of outcome probabilities includes
unpublished data from three studies in addition to the 14
studies previously included in the 2011 Cochrane analysis
for this outcome. Compared to this earlier analysis, the
added data slightly increase the pooled relative risk (from
1.74 to 1.80) and maintain the finding that all studiesFigure 2 Meta-regression of the effect of decision aid quality: normal
et al. [36] is excluded since this decision aid was not available for scoring o
proportional to the weight for that study. IPDASi, International Patient Decuniformly favor decision aids; additionally, they slightly in-
crease the level of heterogeneity (from I2 of 83% to 87%)
[7]. As recognized in the previous Cochrane review [10],
this substantial level of heterogeneity limits the interpret-
ability of the random effects pooled estimate since it rep-
resents an average of possible real effects of decision aids
that vary widely from setting to setting. Thus an investiga-
tion of the factors that may influence this variation is
warranted to better understand the conditions under
which decision aids have their greatest effects [2,3,5,6].
Given that factors underlying real variation of inter-
vention effects can include study-level characteristics of
the comparator or control intervention, the active inter-
vention or the study population [2,3], the current investi-
gation therefore analyzed the effects of three covariates
chosen to represent each of these sources of variability.
There was no evidence that the type of control interven-
tion modifies either the effect size or the control event
rate. This negative finding provides incidental support for
an assumption integral to the third covariate analysis of ef-
fect modification by control event rate (see Methods).
That is, any effect modification is unlikely to be con-
founded by the control intervention manipulating effect
size via effects on the control event rate. Thus the control
event rate can be more reliably interpreted as representing
a study population’s baseline level of knowledge of out-
come probabilities.
The second covariate, decision aid quality as repre-
sented by the IPDASi probabilities dimension score, was
found to modify effect size, the positive relationship ob-
served being consistent with the expectation that higher-
quality decision aids produce larger effect sizes. Overall,
this result provides tentative support for the predictive
validity of the probabilities dimension of the IPDASi,ized IPDASi probabilities dimension score vs ln(OR). Kuppermann
n the IPDASi probabilities dimension. The area of each circle is
ision Aid Standards instrument; OR, odds ratio.
Figure 3 Meta-regression of the effect of control event rate: logit control vs ln(OR). The dashed line is prior to bias correction. The solid
line is after bias correction. The area of each circle is proportional to the weight for that study. OR, odds ratio.
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Significance is lost, for example, when IPDASi probabil-
ities dimension score is combined in multiple regression
with control event rate – although for any bivariate regres-
sion to be sufficiently powered, a larger sample size would
generally be advisable. Thus, additional studies are neces-
sary to improve certainty regarding effect modification
due to the IPDASi probabilities dimension score.
Nevertheless, there are reasons to expect that decision
aid quality defined according to the IPDASi probabilities
dimension does in reality modify the effectiveness of deci-
sion aids. Firstly, individual components of decision aid de-
sign on which the IPDASi probabilities dimension are
based [14] are supported by a review of evidence providing
biologic or theoretical plausibility [15]. Secondly, subgroup
analysis in the 2011 Cochrane review provides direct evi-
dence for at least one design feature – that using numbers
rather than words in decision aids to communicate prob-
abilities improves knowledge of those probabilities to a sta-
tistically significantly greater extent [7]. The componentsTable 3 GRADE [20] evidence quality assessment for the effec
of outcome probabilities
Risk of bias Inconsistency Indirectness
Seriousa No serious inconsistencyb No serious indirectness
a. Study-level risk of bias assessments reported in the 2011 Cochrane update were
assessments were more appropriate (blinding and incomplete outcome data). No s
6 low), or allocation concealment (6 were unclear and 11 low). Only two studies rep
McAlister et al. [29]) had a high risk of bias due to incomplete outcome data (1 was
due to inadequate blinding of outcome assessment (4 were evidently unclear and 3
outcome probabilities was generally assessed using objective a priori criteria, thus i
studies of decision aids do not blind the personnel delivering the intervention, and
b. Inconsistency was not rated down since there was a uniform direction of effect w
heterogeneity is explained by the variation in the control event rate.
c. Imprecision was not rated down since the confidence intervals for the pooled RR
lower control event rates), and this estimate is based on over 2,000 patients in each
d. Investigation of reporting bias using funnel plots was not feasible for this outcom
search and discussion provided in an earlier Cochrane update.of decision aid design that may underlie variation in effect
sizes are not restricted to the IPDASi probabilities domain,
however, and the updated IPDAS review summarizing re-
cent evidence for presenting probabilities [9] describes
additional promising factors to explore in future analyses
of effect modification. The effects of individual design fac-
tors were not examined here because of the top-down ap-
proach to selecting covariates and the decision to restrict
their number to minimize the risk of detecting spurious ef-
fect modification due to multiple comparisons. The selec-
tion of specific factors for future analyses should consider
both the theoretical plausibility of effect modification, and
whether the selected design feature is likely to be consist-
ently relevant for all decision aids since some features,
such as those relevant only to screening decisions, restrict
the sample size of studies available for analysis.
For the third covariate, control event rate, the nega-
tively sloped relationship is highly significant (P = 0.001)
and is slightly steeper after correcting for dependence
of the effect measure on the control event rate, increasingt of decision aids on the accuracy of patient knowledge
Imprecision Publication bias Quality
No serious imprecisionc Unlikelyd ⊕⊕⊕Ο
MODERATE
used, except for two newly extracted risk of bias items where outcome-level
tudies had a high risk of bias due to sequence generation (11 were unclear and
resenting a small weighting in the pooled analysis (Lerman et al. [28] and
unclear and 14 low). Ten studies could be considered to have a risk of bias
were evidently low), but for these studies the accuracy of knowledge of
nadequate blinding of outcome assessment was not considered serious. Most
risk of bias was rated down for this reason.
ith all studies favoring decision aids and a large proportion of the
are uniformly greater than 1.25 (with greater relative effects predicted for
arm.
e. Reporting bias was considered unlikely based on the thoroughness of the
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combined in multiple regression with IPDASi probabilities
dimension scores added to the model, control event rate
remained significant despite the low power for this bivariate
analysis. In univariate analysis, approximately half the het-
erogeneity is accounted for by the control event rate. Thus
control event rate, reflecting patients’ baseline level of know-
ledge of outcome probabilities, appears to be an important
variable explaining heterogeneity of effects of decision aids
on accuracy of knowledge of outcome probabilities, with
greater relative effects expected when the baseline propor-
tion of patients with accurate knowledge is lower.
The precise relationship between control event rate and
effect size is not intuitive from the meta-regression in
Figure 3, since both variables are on the logarithmic scale.
To facilitate interpretation, the relationship was back-
translated to show how the effect sizes are expected to
vary over a range of control event rates, using relative risk,
the effect measure commonly reported in the literature.
The relationship thus represented in Figure 4 could have
various predictive uses, such as for planning future trials
evaluating decision aids. For example, when a control
event rate of 0.5 is anticipated based on pilot work, the
corresponding expected relative risk (of 1.4) could inform
decisions about proceeding with the full trial.
Given the clinical utility of being able to define what
types of patients benefit most from an intervention
using the relationship between effect size and the con-
trol event rate (or level of baseline risk), one may ask
how often is such a relationship significant for interven-
tions in other contexts, and why is it not characterized
more frequently? An analysis by Schmid and colleaguesFigure 4 Empirically fitted relationship predicting relative risk when t
event rate; RR, relative risk.provides an informative answer [5]. They examined 115
meta-analyses of clinical trials to detect whether there was
an effect of control event rate on effect size. After
correcting for dependence of the effect measure on con-
trol event rate and using a two-standard error rule of sig-
nificance, they found linear correlations with ln(OR) in
only 14% of meta-analyses. They proposed that such effect
modification is more likely to be found when the meta-
analysis includes a sufficient number of studies (ten or
more), and comprises greater variation in control event
rates across included studies. The current meta-analysis,
which includes 17 studies and has widely ranging control
event rates (0.08 to 0.77), is consistent with this observa-
tion. This follows from the idea that ‘heterogeneity is your
friend’ since more heterogeneity provides a better oppor-
tunity to detect a covariate effect [38,39].
Finally, by providing an explanation for heterogeneity,
the quality of the pooled research was assessed with the
GRADE framework [19,20] as ‘moderate’ instead of
‘low’. This reflects that the current investigation of
sources of heterogeneity improves the quality of the evi-
dence from a body of 17 pooled studies by improving its
interpretability and utility [2-4].
A limitation of investigating study-level sources of het-
erogeneity is that interpretation may be affected by
confounding from other study-level factors, particularly
those related to study design [2]. These factors include
both methodological aspects known to increase the risk of
bias in an RCT (sequence generation, allocation conceal-
ment, blinding of patients, blinding of intervention pro-
viders, blinding of outcome assessors, and completeness
of outcome data) and aspects of outcome measurementhe control event rate (baseline knowledge) is known. CER, control
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quires considering characteristics of the questions used to
measure knowledge of probabilities. Evaluation questions
can vary, for example, in the number of categories to se-
lect between within a multiple choice question, whether
the question forces guessing (by not providing an option
for ‘unsure’), whether numbers or words are used to rep-
resent probabilities, and in the precision used to define
the probability ranges for each category. Some but not all
of these characteristics are also design features of decision
aids whose influence on improving knowledge of probabil-
ities has been established – for example, that presenting
probabilities as numbers is more effective than words
[7,40,41]. Similarly, specific characteristics would be
expected to influence the difficulty of evaluation questions.
Although there is extensive research and standards that
guide and support the presentation of probabilities in de-
cision aids [14,15], research into how relevant characteris-
tics affect the difficulty of evaluation questions – and
therefore influence the measurement of patient knowledge
of probabilities – is lacking. It was not possible to conduct
an analysis of these effects in the current study since de-
scriptions of evaluation questions were not available for
most studies. Considering how question difficulty has the
potential to influence and confound estimates of baseline
knowledge (control event rates), future research into this
measurement issue is warranted.
Conclusions
The current sub-analysis increases the interpretability and
utility of previously pooled evidence on the effects of deci-
sion aids for improving accuracy of knowledge of outcome
probabilities by adding data for this outcome and charac-
terizing the effects of two potential contributors to hetero-
geneity of decision aid effects: decision aid quality and the
control event rate. While decision aid quality, as measured
by the IPDASi probabilities dimension, may increase the
effects of decision aids, this finding is of borderline signifi-
cance and requires further analysis with data from add-
itional studies. The control event rate – representing
patients’ baseline level of knowledge of outcome probabil-
ities – is a highly significant and substantial contributor to
heterogeneity, with greater relative effects observed when
the baseline proportion of patients with accurate know-
ledge is low. This suggests that decision aids are most
effective in populations with low awareness. Further re-
search may be warranted, however, to determine whether
aspects of evaluation questions influence the measure-
ment of knowledge of probabilities. Knowledge of how
relative risk is expected to vary across a wide range of con-
trol event rates may be useful to inform policy judgments
about the uptake of decision aids to inform patients of
probabilities related to the outcomes of interventions or
diagnostic tests in specific settings.Abbreviations
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